Hypotension duration and vasopressor requirements following intrathecal oxytocin for Total hip arthroplasty: Secondary analysis of a randomized controlled trial
Authors' conclusion
The administration of 100 μg of intrathecal oxytocin does not significantly impact the duration of hypotension or the need for vasopressor agents when given as a component of a spinal anesthetic.
Study context
- Population
- Patients undergoing primary total hip arthroplasty under spinal anesthesiaincluded in the analysis
- Participants
- 90 patients
- Comparison
- Intrathecal oxytocin 100 μg vs placebo with spinal anaesthetic
- Oxytocinn = 44
- Placebon = 46reference
- Primary endpoint
- Duration of hypotension (minutes with MAP < 65 mmHg) and cumulative vasopressor requirements
- Follow-up
- Initial 60 min following spinal placement
Methodological detailsplacebo-controlled, prospective data supplemented with retrospective data
- Placebo-controlled
- Prospective data supplemented with retrospective data
Primary result
As reported in the abstract
Duration of hypotension · first 60 min
P = 0.476
Secondary outcomes
Cumulative vasopressor requirements (phenylephrine equivalents) · first 60 min after spinal placement
- No difference in cumulative vasopressor requirements, oxytocin vs placebo: 1303 ± 883 vs 1156 ± 818 μg (phenylephrine equivalents)
- P = 0.413
- Co-primary outcome
Secondary outcomes (later hypotension durations and vasopressor requirements, perioperative fluids, physical therapy metrics, time to first opioid, cumulative opioid and verbal pain scores through 24 h)
- No group differences for any secondary outcome
Original publication
Hypotension duration and vasopressor requirements following intrathecal oxytocin for Total hip arthroplasty: Secondary analysis of a randomized controlled trial. J Clin Anesth. Published 23 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →